Articles

Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients

Abstract

Myelodysplastic syndrome is a bone marrow failure in which differentiation and maturity do not happen naturally and dysplasia exists in each of 3 cell categories in Bone marrow. Refractory anemia is one of the major complaints with which the patients come to hematology clinics, which in diagnostic considerations lead to MDS as diagnosis. Often there is no recognized reason for this, so it is called "primary MDS". In practice, we meet some patients who have MDS criteria however we can also find specific reasons for it; therefore we call it "secondary MDS". One of the most important reasons for secondary MDS is the side effects of medications used in chemotherapy and radiotherapy in patients who undergo these therapies. We observed 6 patients in this case study during lengthy follow up that were diagnosed as MDS and during follow up period malignancy appeared in 6 cases. Supportive and therapeutic measures in these patients did not considerably improve blood cell count, most patients required blood injection and antibiotics for infection treatment. However align with malignancy treatment such problems are completely resolved both in terms of clinical and laboratory.

Greenberg PL. The smoldering myeloid leukemia states: clinical and biologic features. Blood 1983; 61:1035–1044.

Koeffler HP, Golde DW. Human preleukemia. Ann Intern Med 1980; 93: 347–353.

Noel P, Solberg LA Jr. Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol 1992; 12:193–215.

Doll DC, List AF. Myelodysplastic syndromes. West J Med 1989; 151:161–167.

Williamson PJ, Kruger AR, Reynolds PJ, et al. establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87:743–745

Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82: 358–367.

Pomeroy C, Oken MM, Rydell RE, et al. Infection in the myelodysplastic syndromes. Am J Med 1991; 90:338–344

Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000; 95:3273–3279.

Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95:1588–1593.

Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015–2023.

Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:9–16

Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19:47–84

Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189–199

Nowell PC. Chromosome abnormalities in myelodysplastic syndromes. Semin Oncol 1992; 19:25–33.

Kuriyama K, Tomonaga M, Matsuo T, et al. Diagnostic significance of detecting pseudo–Pelger-Huet anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol 1986;63:665–669

Sans-Sabrafen J, Buxó-Costa J, Woessner S, Florensa L, Besses C, Malats N, Porta M. Myelodysplastic syndromes and malignant solid tumors: analysis of 21 cases.Am J Hematol. 1992 Sep; 41(1):1-4.

Enright H, Jacob HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995;91:403–408

Files
IssueVol 7, No 2 (2013) QRcode
SectionArticles
Keywords
Malignancy Myelodysplastic syndrome Paraneoplastic syndrome

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Aznab M, Kavianymoghadam K. Secondary Myelodysplastic Syndrome May Happen Same as Paraneoplastic Syndrome in a Period of Time and Prior to The Appearance of Malignancy: A case Study of 6 Patients. Int J Hematol Oncol Stem Cell Res. 1;7(2):30-33.